More than part of the long-term source of COVID-19 vaccine applicants has already taken over a small organization of countries, according to a report by Oxfam International.
The nonprofit warned that countries representing only 13% of the world’s population have already taken 51% of the promised doses of major COVID-19 vaccine candidates.
A major fear around the long-awaited COVID-19 vaccine is dose availability and equitable distribution around the world, a sentiment that would have been repeated through Melinda Gates.
The report noted that the same pharmaceutical corporations that have recently competed to expand the vaccine do not have the ability to produce sufficient doses for all who want it.
Covid-19 vaccine
Frequently Asked Questions
Citing the knowledge provided through corporate Analysis Airfinity, Oxfam said that of the nine COVID-19 vaccines that are recently found in phase 3 clinical trials, agreements have been made public for five, which are being developed through AstraZeneca, Gamaleya/Sputnik, Moderna, Pfizer and Sinovac.
For COVID-19 vaccine updates, click here.
“Even on the highly unlikely occasion when all five vaccines succeed, nearly two-thirds (61%) will not have a vaccine until at least 2022. Some of these experiments are much more likely to fail, leaving the number of others without even greater access,” Oxfam said.
According to the report, Moderna’s vaccine candidate, who has one of the leading candidates, “received $2. 48 billion in cash from committed taxpayers. “But the company sold features from all its sources to rich countries, at costs ranging from $12 to $16 per year. dose in the US. U. S. to about $35 a dose in other countries.
In addition, several reports imply that the company has the capacity to produce 475 million people, or 6% of the world’s population.
One calculation placed the combined production capacity of the five candidate vaccines at 5. 94 billion doses, “sufficient for another 2. 97 billion people as the five long-term vaccines will or will most likely require two doses,” the report said.
“Supply agreements have already been concluded for 5,303 billion doses, of which 2,728 billion (51%) they were purchased through evolved countries, adding the United Kingdom, the United States, Australia, Hong Kong and Macau, Japan, Switzerland and Israel, as European countries. The remaining 2,575 million doses were purchased or promised to the next countries, adding India, Bangladesh, China, Brazil, Indonesia and Mexico,” he added.
Another report reiterated the need for equitable distribution of life-saving vaccines. The Goalkeepers 2020 report published through the Bill and Melinda Gates Foundation earlier this week notes that if rich countries buy the first 2 billion doses of vaccine, make sure they are distributed proportionally to the world’s population, then nearly twice as many people can die simply by COVID-19.
Coronavirus’s essential SOP on reopening cinemas and schools; Dr. Reddy’s to protocol for vaccine testing in Russia